This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.

Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted and the elements of each edition are presented as a set of blog posts at https://centerforvaccineethicsandpolicy.net. This blog allows full text searching of over 23,000 entries.

Comments and suggestions should be directed to
David R. Curry, MS
Editor and
Executive Director
Center for Vaccine Ethics & Policy
david.r.curry@centerforvaccineethicsandpolicy.org

Request email delivery of the pdf: If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to david.r.curry@centerforvaccineethicsandpolicy.org.

Support this knowledge-sharing service: Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click here to donate and thank you in advance for your contribution.

Contents [click on link below to move to associated content]
A. Milestones :: Perspectives :: Featured Journal Content
B. Emergencies
C. WHO; CDC [U.S., Africa, China]
D. Announcements
E. Journal Watch
Editor’s Note:
As is obvious to all, the sheer volume of strategic announcements, regulatory actions, country program decisions, commentary, and, indeed, misinformation around COVID response continues at extraordinary levels. Our weekly digest strives to present a coherent and comprehensive snapshot, but cannot be exhaustive. If you recognize a missed strategic development, a new source of rigorous analysis, or an insight/commentary that would benefit our common understanding, please advise me...we will review all suggestions and consider for inclusion in a subsequent edition: david.r.curry@ge2p2global.org

We are seeking access to modelling which engages scenarios and articulates imperatives around a pandemic end-game through at least a 2025 horizon. We assess that WHO must be conducting or contracting for such modeling – or should recognize an imperative to be doing so in its global health governance role. If we have missed such modeling in progress, we would be delighted to be advised of it and will include it in our coverage.

COVID Vaccines – OCHA:: HDX

COVID-19 Data Explorer: Global Humanitarian Operations
COVID-19 Vaccine Roll-out
Sep 04, 2021 | COVAX (WHO,GAVI,CEPI), UNDESA, Press Reports | DATA
Global COVID-19 Figures: 219M total confirmed cases; 4.5M total confirmed deaths
Global vaccines administered: 5.44B
Number of Countries: 29 [26]
COVAX Allocations Round 4-6 (Number of Doses): 120M
COVAX Delivered (Number of Doses): 74M [68M week ago]
Other Delivered (Number of Doses): 110M [98M week ago]
Total Delivered (Number of Doses): 180M [170M week ago]
Total Administered (Number of Doses): 160M [140M week ago]

A joint initiative from the International Monetary Fund, World Bank Group, World Health Organization, and World Trade Organization to accelerate access to COVID-19 vaccines, therapeutics and diagnostics by leveraging multilateral finance and trade solutions, particularly in low- and middle-income countries.
Website accessed 04 Sep 2021: https://data.covid19taskforce.com/data. The global view below is complemented by country-specific dashboards here.
Population

- Total Population: 7.7B people
- Target Population for Vaccination (end 2021): 3.1B people (40% of total)
- Target Population for Vaccination (mid 2022): 4.6B people (60% of total)
- Fully Vaccinated Population: 2.1B people (27.6% of total)

Doses

- Required Doses (end 2021): 6.2B doses (40% of total population)
- Required Doses (mid 2022): 9.3B doses (60% of total population)
- Secured Vaccines / Expected Vaccine Supply: 15.7B doses
- Delivered Doses: 5.6B doses
- Doses Administered: 5.3B doses
World Bank Vaccine Operations Portal
As of July 29, 2021, the World Bank approved operations to support vaccine rollout in 54 countries amounting to $4.6 billion. See the latest project financing, project documents and procurement information in the list below:

Countries receiving World Bank support for vaccines
As of July 29, 2021
This list of countries, project documents, and procurement notices and contracts will be updated as data becomes available.

Coronavirus [COVID-19] - WHO
Public Health Emergency of International Concern (PHEIC)
https://www.who.int/emergencies/diseases/novel-coronavirus-2019

Weekly Epidemiological and Operational updates
Last update: 3 Sep 2021
Confirmed cases :: 218 946 836 [214 468 601 week ago]
Confirmed deaths :: 4 539 723 [4 470 969 week ago]
Vaccine doses administered: 5 289 724 918 [4 953 887 422 week ago]

WHO, Germany open Hub for Pandemic and Epidemic Intelligence in Berlin
New hub’s mission is to provide the world with better data, analytics and decisions to detect and respond to health emergencies
1 September 2021  News release  Berlin
To better prepare and protect the world from global disease threats, H.E. German Federal Chancellor Dr Angela Merkel and Dr Tedros Adhanom Ghebreyesus, World Health Organization Director-General, will today inaugurate the new WHO Hub for Pandemic and Epidemic Intelligence, based in Berlin.

“The world needs to be able to detect new events with pandemic potential and to monitor disease control measures on a real-time basis to create effective pandemic and epidemic risk management,” said Dr Tedros. “This Hub will be key to that effort, leveraging innovations in data science for public health surveillance and response, and creating systems whereby we can share and expand expertise in this area globally.”
The WHO Hub, which is receiving an initial investment of US$ 100 million from the Federal Republic of Germany, will harness broad and diverse partnerships across many professional disciplines, and the latest technology, to link the data, tools and communities of practice so that actionable data and intelligence are shared for the common good.

The WHO Hub is part of WHO’s Health Emergencies Programme and will be a new collaboration of countries and partners worldwide, driving innovations to increase availability of key data; develop state of the art analytic tools and predictive models for risk analysis; and link communities of practice around the world. Critically, the WHO Hub will support the work of public health experts and policy-makers in all countries with the tools needed to forecast, detect and assess epidemic and pandemic risks so they can take rapid decisions to prevent and respond to future public health emergencies.

“Despite decades of investment, COVID-19 has revealed the great gaps that exist in the world’s ability to forecast, detect, assess and respond to outbreaks that threaten people worldwide,” said Dr Michael Ryan, Executive Director of WHO’s Health Emergency Programme. “The WHO Hub for Pandemic and Epidemic Intelligence is designed to develop the data access, analytic tools and communities of practice to fill these very gaps, promote collaboration and sharing, and protect the world from such crises in the future.”

The Hub will work to:

▪ Enhance methods for access to multiple data sources vital to generating signals and insights on disease emergence, evolution and impact;
▪ Develop state of the art tools to process, analyze and model data for detection, assessment and response;
▪ Provide WHO, our Member States, and partners with these tools to underpin better, faster decisions on how to address outbreak signals and events; and
▪ Connect and catalyze institutions and networks developing disease outbreak solutions for the present and future.

Dr Chikwe Ihekweazu, currently Director-General of the Nigeria Centre for Disease Control, has been appointed to lead the WHO Hub. WHO would like to acknowledge the Nigerian government for its support, which ensures strong leadership for this important initiative...

:::::

3 September 2021  Remarks
Director-General’s opening remarks at Building Resilience Through Innovation in Response to the COVID-19 Pandemic in LDCs Islamic Development Bank

1 September 2021  Remarks
Dr Michael Ryan’s remarks at the launch of the WHO Hub for Pandemic and Epidemic Intelligence

1 September 2021  Remarks
Director-General’s opening remarks at the Memorandum of Understanding with the Robert Koch Institute
Remarks

Director-General’s remarks at the inauguration of the WHO Hub for Pandemic and Epidemic Intelligence

 wagon

31 August 2021


COVID-19

Objectives

The response to the global COVID-19 pandemic crisis has exacerbated the need for rapid evidence-based assessments of innovative health technologies to ensure safe and appropriate use. Thus, the objectives of the 2021 compendium are to:

1. Select innovative technologies that can have an immediate or future impact on the COVID-19 preparedness and response, have the potential to improve health outcomes and quality of life, and/or offer a solution to an unmet medical/health technology need by evaluating their appropriateness, quality, and safety.

2. Shed light on advantages and challenges associated with the adoption of innovative health technologies in low-resource settings.

3. Acknowledge some success stories and, at the same time, raise awareness of the pressing need for appropriate and affordable design solutions and encourage more innovative efforts in the field.

4. Encourage greater interaction among the ministries of health, procurement officers, donors, technology developers, manufacturers, clinicians, academics and the general public to ensure greater investment in appropriate health technology and a move toward universal access to essential health technologies.

5. Support informed procurement decisions by NGOs, governments, and other stakeholders.

Weekly operational update on COVID-19 - 30 August 2021

Overview

In this edition of the COVID-19 Weekly Operational Update, highlights of country-level actions and WHO support to countries include:

▪ GeneXpert machine donated to Belize’s Central Medical Laboratory
▪ Supporting quality management implementation, coordination and costing as part of the COVID-19 laboratory response in Kyrgyzstan
▪ 15 000 kg of medical supplies arrive in Fiji to support the response to a surge in COVID-19 cases
▪ Extending COVID-19 vaccination to Rohingya refugees in Cox’s Bazar camps in Bangladesh
▪ Responding to COVID-19 in Jordan: The Innovative Use of Online Platforms
▪ The Elsje Finck-Sanichar College COVAB in Suriname embraces OpenWHO and online learning during COVID-19 pandemic
▪ Progress on a subset of indicators from the SPRP 2021 Monitoring and Evaluation Framework
▪ Updates on WHO’s financing to support countries in SPRP 2021 implementation and provision of critical supplies.

Weekly epidemiological update on COVID-19 - 31 August 2021

Overview
With just under 4.4 million new cases reported this week (23-29 August), the number of new cases reported globally remains similar to the previous week after increasing for nearly two months (since mid-June). In the past week all regions reported either a decline (Africa, Americas) or a similar trend (Europe, South-East Asia, Eastern Mediterranean) in new cases, except for the Western Pacific Region which reported a 7% increase as compared to previous week. The number of deaths reported globally this week were also similar to last week, with just over 67,000 new deaths reported. The Eastern Mediterranean and Western Pacific Regions reported an increase in the number of weekly deaths, 9% and 16% respectively, while the South-East Asia Region reported the largest decrease (20%). The cumulative number of cases reported globally is now nearly 216 million and the cumulative number of deaths is just under 4.5 million.

In this edition, a special focus update is provided on:

- SARS-CoV-2 Variants of Concern (VOCs) Alpha, Beta, Gamma and Delta which includes updates on the geographic distribution of these VOCs as well as a description of a newly classified Variant of Interest (VOI), Mu.

“...Based on the latest round of assessments, B.1.621 was classified as a VOI on 30 August 2021 and given the WHO label “Mu”. This includes the descendent Pango lineage B.1.621.1. This variant is known as 21H in Nextstrain nomenclature. The Mu variant has a constellation of mutations that indicate potential properties of immune escape. Preliminary data presented to the Virus Evolution Working Group show a reduction in neutralization capacity of convalescent and vaccinee sera similar to that seen for the Beta variant, but this needs to be confirmed by further studies.

Since its first identification in Colombia in January 2021, there have been a few sporadic reports of cases of the Mu variant and some larger outbreaks have been reported from other countries in South America and in Europe. As of 29 August, over 4500 sequences (3794 sequences of B.1.621 and 856 sequences of B.1.621.1) have been uploaded to GISAID from 39 countries. Although the global prevalence of the Mu variant among sequenced cases has declined and is currently below 0.1%, the prevalence in Colombia (39%) and Ecuador (13%) has consistently increased....”

---

**Figure 1. COVID-19 cases reported weekly by WHO Region, and global deaths, as of 29 August 2021**
Status of COVID-19 Vaccines within WHO EUL/PQ evaluation process  19 August 2021
For 22 vaccine candidates, presents Manufacturer, Name of Vaccine, NRA of Record, Platform, EOI Accepted Status, Pre-submission Meeting Held Status, Dossier Accepted for Review, Status of Assessment; Anticipated/Completed Decision Date
[No updates since 19 Aug 2021]

COVID Vaccine Developer/Manufacturer Announcements
[relevant press releases/announcement from organizations from WHO EUL/PQ listing above]

AstraZeneca
Press Releases
AstraZeneca and European Commission reach settlement agreement over vaccine supply, ending litigation
03 September 2021
AstraZeneca and the European Commission have reached an agreement that ends legal proceedings over the execution of the Advance Purchase Agreement for the delivery of the COVID-19 vaccine Vaxzevria (ChAdOx1-S [Recombinant]).
Under the agreement, AstraZeneca commits to deliver 60 million doses of the vaccine by the end of the third quarter 2021, 75 million by the end of the fourth quarter 2021 and 65 million by the end of the first quarter 2022. Member States will be provided with regular delivery schedules, and capped rebates will apply in the event of any delayed doses...

BioCubaFarma – Cuba
Últimas Noticias - [Website not responding at inquiry; receiving 403-Forbidden]

CanSinoBIO
News - [Website not responding at inquiry]

Clover Biopharmaceuticals - China
News - No new digest announcements identified

Curevac  [Bayer Ag – Germany]
News
CureVac’s CVnCoV Phase 2b/3 Study Data Published in Preprints with The Lancet
TÜBINGEN, Germany / BOSTON, USA – August 31, 2021
CureVac N.V. (Nasdaq: CVAC), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (“mRNA”), today announced the publication of its pivotal Phase 2b/3 (HERALD study) primary data of CVnCoV, its first-generation COVID-19 vaccine candidate, in Preprints with The Lancet. The HERALD study enrolled approximately 40,000 participants in ten countries across Latin America and Europe, in the predefined age groups 18 to 60 and above 60. For the final analysis, COVID-19 cases were caused by 15 different virus variants...

Gamaleya National Center
Janssen/JNJ

Press Releases
Aug 31, 2021 United States
Johnson & Johnson and Global Partners Announce Results from Phase 2b Imbokodo HIV Vaccine Clinical Trial in Young Women in Sub-Saharan Africa
:: Investigational vaccine candidate did not provide sufficient protection against HIV infection
:: No vaccine-related safety signals identified
:: J&J HIV vaccine program continues with global Phase 3 Mosaico HIV study evaluating a different composition of the vaccine regimen in different populations

Moderna

Press Releases
September 3, 2021
Moderna Announces Submission of Data to European Medicines Agency for its COVID-19 Vaccine Booster
mRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40 times against the Delta variant (B.1.617.2)

September 1, 2021
Moderna Announces Submission of Initial Data to U.S. FDA for Its COVID-19 Vaccine Booster
mRNA-1273 at 50 µg dose level induced robust antibody responses of more than 40 times against the Delta variant (B.1.617.2)

Novavax

Press Releases - No new digest announcements identified
Novavax Statement on CDC Guidance Update for COVID-19 Clinical Trial Participants
Aug 30, 2021
...the U.S. Centers for Disease Control and Prevention (CDC) has provided updated guidance for those who have been vaccinated as part of a clinical trial in the U.S. The CDC guidance states that participants in the Novavax PREVENT-19 Phase 3 clinical trial meet the criteria to be considered fully vaccinated two weeks after they have completed the vaccine series...

Pfizer

Recent Press Releases
09.02.2021
Pfizer Announces Start of Phase 3 Clinical Trial in Adults for Its Investigational Vaccine Against Respiratory Syncytial Virus (RSV)
First subjects vaccinated in study of Pfizer’s RSV bivalent prefusion F subunit investigational vaccine candidate in adults ages 60 or older
RSV is a common and pervasive cause of severe acute respiratory illness in older adults with no vaccine currently available
Sanofi Pasteur
Press Releases - No new digest announcements identified

Serum Institute of India
NEWS & ANNOUNCEMENTS - No new digest announcements identified

Sinopaharm/WIBPBIBP
News - [Website not responding at inquiry]

Sinovac
Press Releases - No new digest announcements identified

Vector State Research Centre of Viralogy and Biotechnology
Home - No new digest announcements identified

Zhifei Longcom, China
[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.] [No website identified]

GSK
Press releases for media
31 August 2021
SK bioscience and GSK start Phase 3 trial of adjuvanted COVID-19 vaccine candidate
:: Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data
:: Global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
:: Aim is for global supply through the COVAX facility in the first half of 2022, subject to data and regulatory review

SK Biosciences
Press releases - No new digest announcements identified

UNICEF COVID-19 Vaccine Market Dashboard :: Agreements Table Accessed 04 Sep 2021
An overview of information collected from publicly announced bilateral and multilateral supply agreements [agreements view since last week’s edition]

- 24 vaccines approved for use by at least one national regulatory authority
- 7 vaccines in WHO’s Emergency Use Listing
- 18.3bn doses secured globally
- $2–$37 reported vaccine price range per dose
- 5.09bn doses COVAX has secured, optioned, or received as donations
- 236.2M doses shipped through COVAX to 139 countries

No new bilateral deals reported.
**Duke – Launch and Scale Speedometer**

**The Race for Global COVID-19 Vaccine Equity**

A flurry of nearly 200 COVID-19 vaccine candidates are moving forward through the development and clinical trials processes at unprecedented speed; more than ten candidates are already in Phase 3 large-scale trials and several have received emergency or limited authorization. Our team has aggregated and analyzed publicly available data to track the flow of procurement and manufacturing and better understand global equity challenges. We developed a data framework of relevant variables and conducted desk research of publicly available information to identify COVID vaccine candidates and status, deals and ongoing negotiations for procurement and manufacturing, COVID burden by country, and allocation and distribution plans. We have also conducted interviews with public officials in key countries to better understand the context and challenges facing vaccine allocation and distribution

[accessed 24 July 2021]

See our COVID Vaccine Purchases research
See our COVID Vaccine Manufacturing research
See our COVID Vaccine Donations & Exports research

**Global Dashboard on COVID-19 Vaccine Equity**

The Dashboard is a joint initiative of UNDP, WHO and the University of Oxford with cooperation across the UN system, anchored in the SDG 3 Global Action Plan for Healthy Lives and Well-being for All.


See also visualization on Vaccine Access and Vaccine Affordability
High income countries have to increase their health care spending by 0.8% on average to cover cost of vaccinating 70% of the population.

Low income countries have to increase their health care spending by 56.6% on average to cover cost of vaccinating 70% of the population.

UNDP Survey, WHO, UNICEF
Our World in Data
Coronavirus (COVID-19) Vaccinations  [Accessed 04 Sep 2021]

- **40.2%** of the world population has received at least one dose of a COVID-19 vaccine.
- **5.44 billion doses** have been administered globally, and **35.64 million** are now administered each day.
- Only **1.8%** of people in low-income countries have received at least one dose.
Daily COVID-19 vaccine doses administered per 100 people, Sep 3, 2021

Shown is the rolling 7-day average per 100 people in the total population. For vaccines that require multiple doses, each individual dose is counted.

Source: Official data collated by Our World in Data – Last updated 4 September 2021, 09:00 (London time)

COVID-19 vaccine doses administered per 100 people, Sep 3, 2021

For vaccines that require multiple doses, each individual dose is counted. As this same person may receive more than one dose, the number of doses per 100 people can be higher than 100.

Source: Official data collated by Our World in Data – Last updated 4 September 2021, 09:00 (London time)
CDC Statement Following ACIP Pfizer-BioNTech Vote
Monday, August 30, 2021

Today, CDC Director Rochelle P. Walensky, M.D., M.P.H., endorsed the CDC Advisory Committee on Immunization Practices’ (ACIP) recommendation for use of the Pfizer-BioNTech’s licensed vaccine for people 16 and older.

This recommendation follows FDA’s decision to fully approve Pfizer’s COVID-19 vaccine.

The ACIP recommendation comes 9 months after the committee’s interim recommendation and after an exhaustive review of the scientific evidence demonstrating safety and effectiveness, and supporting continued use of the vaccine.

“We now have a fully approved COVID-19 vaccine and ACIP has added its recommendation. If you have been waiting for this approval before getting the vaccine, now is the time to get vaccinated and join the more than 173 million Americans who are already fully vaccinated,” said CDC Director Dr. Rochelle Walensky.

Vaccines and Related Biological Products Advisory Committee- FDA

:: Vaccines and Related Biological Products Advisory Committee September 17, 2021 Meeting Announcement

Agenda

...The committee will meet in open session to discuss the Pfizer-BioNTech supplemental Biologics License Application for COMIRNATY for administration of a third dose, or “booster” dose, of the COVID-19 vaccine, in individuals 16 years of age and older. Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides (LBP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER). Also, on September 30, 2021, under Topic II, the Center for Biologics Evaluation and Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 southern hemisphere influenza season. Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides (LBP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER). Also, on September 30, 2021, under Topic II, the Center for Biologics Evaluation and Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 southern hemisphere influenza season. Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides (LBP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER). Also, on September 30, 2021, under Topic II, the Center for Biologics Evaluation and Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 southern hemisphere influenza season.
Vaccines and Related Biological Products Advisory Committee September 30, 2021
Meeting Announcement - 09/30/2021 - 09/30/2021

Agenda

...Under Topic I, the committee will meet in open session to hear an overview of the research programs in the Laboratory of Bacterial Polysaccharides (LBP), Division of Bacterial, Parasitic, and Allergenic Products (DBPAP), Office of Vaccines Research and Review (OVRR), Center for Biologics Evaluation and Research (CBER). Also, on September 30, 2021, under Topic II, the Center for Biologics Evaluation and Research’s (CBER) VRBPAC will meet in open session to discuss and make recommendations on the selection of strains to be included in the influenza virus vaccines for the 2021 to 2022 southern hemisphere influenza season.

White House [U.S.]

Briefing Room – Selected Major COVID Announcements

On-the-Record Press Call by Office of Science and Technology Policy Director Dr. Eric Lander and NSC Director for Global Health Security and Biodefense Dr. Beth Cameron on American Pandemic Preparedness

September 03, 2021 • Press Briefings

FACT SHEET: Biden Administration to Transform Capabilities for Pandemic Preparedness

September 03, 2021 • Statements and Releases

Press Briefing by White House COVID-19 Response Team and Public Health Officials

September 02, 2021 • Press Briefings

Press Briefing by White House COVID-19 Response Team and Public Health Officials

August 31, 2021 • Press Briefings

Europe: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment

European Medicines Agency

News & Press Releases

Meeting highlights from the Pharmacovigilance Risk Assessment Committee (PRAC) 30 August – 2 September 2021

News 03/09/2021

COVID-19 vaccines: EMA reviewing cases of multisystem inflammatory syndrome

EMA’s safety committee (PRAC) is assessing whether there is a risk of multisystem inflammatory syndrome (MIS) with COVID-19 vaccines following a report of MIS with Comirnaty. The case occurred in a 17-year old male in Denmark who has since fully recovered.

Some cases of MIS were also reported in the EEA following vaccination with other COVID-19 vaccines.1

MIS is a serious inflammatory condition affecting many parts of the body and symptoms can include tiredness, persistent severe fever, diarrhoea, vomiting, stomach pain, headache, chest pain and
difficulty breathing. MIS has previously been reported following COVID-19 disease. The Danish patient, however, had no history of COVID-19.

MIS is rare and its incidence rate before the COVID-19 pandemic estimated from 5 European countries was around 2 to 6 cases per 100,000 per year in children and adolescents below 20 years of age and below 2 cases per 100,000 per year in adults aged 20 years or more.

At this stage, there is no change to the current EU recommendations for the use of COVID-19 vaccines...

News: ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines (new)
Last updated: 02/09/2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued yesterday by the European Centre for Disease Prevention and Control (ECDC). The report also notes that additional doses should already be considered for people with severely weakened immune systems as part of their primary vaccination.

Evidence on vaccine effectiveness and duration of protection shows that all vaccines authorised in the EU/EEA are currently highly protective against COVID-19-related hospitalisation, severe disease and death, while about one out of three adults in the EU/EEA over 18 years is still currently not fully vaccinated. In this situation, the priority now should be to vaccinate all those eligible individuals who have not yet completed their recommended vaccination course. To complement vaccination efforts, it is also crucial to continue applying measures such as physical distancing, hand and respiratory hygiene, and using face masks where needed, in particular in high-risk settings such as long-term care facilities or hospital wards with patients at risk of severe COVID-19...

::::

European Centre for Disease Prevention and Control
https://www.ecdc.europa.eu/en

Latest Updates
News
ECDC awards 77 M€ to strengthen EU/EEA Member States’ capacities to detect and identify SARS-CoV-2 variants
News story - 3 Sep 2021

ECDC has awarded more than 77 M€ to 24 EU/EEA countries to strengthen whole genome sequencing and RT-PCR infrastructures within the countries’ national public health programmes.

The immediate objective is to reinforce countries’ capacities for early detection and enhanced monitoring of emergent and known SARS-CoV-2 variants. The support is a response to a request to ECDC by the European Commission to implement a number of activities that were launched as part of the “HERA Incubator” aiming to support the rapid detection of SARS-CoV-2 variants across the EU...

News
ECDC and EMA highlight considerations for additional and booster doses of COVID-19 vaccines
Press release - 2 Sep 2021

Based on current evidence, there is no urgent need for the administration of booster doses of vaccines to fully vaccinated individuals in the general population, according to a technical report issued by the European Centre for Disease Prevention and Control (ECDC). The report also notes that additional
doses should already be considered for people with severely weakened immune systems as part of their primary vaccination.

---

**European Centre for Disease Prevention and Control**

COVID-19 Vaccine Tracker

<table>
<thead>
<tr>
<th>Cumulative uptake of at least one dose among adults (18+) in EU/EEA</th>
<th>Cumulative uptake of full vaccination among adults (18+) in EU/EEA</th>
</tr>
</thead>
<tbody>
<tr>
<td>76.8%</td>
<td>69.1%</td>
</tr>
</tbody>
</table>

*Data as of 2021-09-03*  

---

**European Commission**  
*Questions and answers*  
3 September 2021  
**Questions and Answers: The EU and AstraZeneca agree on COVID-19 vaccine supply and on ending litigation**

*Press release*  
3 September 2021  
**Coronavirus: The EU and AstraZeneca agree on COVID-19 vaccine supply and on ending litigation**

Today the EU and AstraZeneca have reached an agreement which will secure the delivery of the remaining COVID-19 vaccine doses to Member States under the terms of the Advance Purchase Agreement concluded on 27 August 2020 with AstraZeneca.

*Press release*  
31 August 2021  
**Coronavirus: 70% of the EU adult population fully vaccinated**

Today, the EU has reached a crucial milestone with 70% of the adult population now fully vaccinated. In total, over 256 million adults in the EU have now received a full vaccine course.

---

**Africa: COVID-19 – Announcements/Regulatory Actions/Deployment**
Africa CDC Vaccine Dashboard

Current at 09/01/2021 Full scale, interactive dashboard available at: https://africacdc.org/covid-19-vaccination/

Russia: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Russia: Sputnik V – "the first registered COVID-19 vaccine"
https://sputnikvaccine.com/newsroom/pressreleases/
Press Releases
Sputnik V demonstrates 94.8% efficacy against COVID during the vaccination campaign in San Marino
Press release, 02.09.2021

India: COVID-19 Vaccines – Announcements/Regulatory Actions/Deployment
Research on link of COVID, cold chain urged
Updated: 2021-09-01 | CHINA DAILY

Chinese researchers are calling for global cooperation to improve understanding of the spread of SARS-CoV-2 via cold chains as part of efforts to trace the origins of the virus.

The first phase of WHO-organized studies into the origins of the virus that causes COVID-19 wrapped up in China in February and identified the cold-chain theory as a possible explanation for its spread across populations.

"The cold-chain industry inherently spans the globe. As we are seeing a large amount of science-based evidence pointing to the virus' spread via cold chains, we suggest the next phase of origin-tracing work involve concerted cold-chain studies under a global framework," Liu Jun, a professor at the National Institute for Viral Disease Control and Prevention of the Chinese Center for Disease Control and Prevention, said on Friday.

He said Chinese scientists will continue to focus on cold-chain products that arrived in Wuhan, Hubei province, in the four months before the virus emerged in the city in late 2019. Samples will be taken and tested from cold storage...
Emergencies

POLIO
Public Health Emergency of International Concern (PHEIC)
https://polioeradication.org/polio-today/polio-now/this-week/

Polio this week as of 02 September 2021

Summary of new WPV and cVDPV viruses this week (AFP cases and ES positives):
:: Pakistan: one WPV1 positive environmental sample
:: Ethiopia: two cVDPV2 cases
:: Gambia: four cVDPV2 positive environmental samples
:: Liberia: one cVDPV2 positive environmental sample
:: Mali: one cVDPV2 case
:: Mauritania: two cVDPV2 positive environmental samples
:: Niger: one cVDPV2 positive environmental sample
:: Nigeria: twenty-three cVDPV2 cases and fifteen cVDPV2 positive environmental samples
:: Senegal: two cVDPV2 positive environmental samples
:: Sierra Leone: one cVDPV2 case
:: Tajikistan: one cVDPV2 case

WHO/OCHA Emergencies

Editor’s Note:
WHO has apparently reorganized and fundamentally shifted how it judges and tracks “emergencies”. We found no announcement of descriptive information to share and present the webpage structure as encountered below. Obviously, the dates associated with some of these emergencies suggest that this is an archival platform as well as a current emergencies resource.

Health emergencies list - WHO
“The health emergencies list details the disease outbreaks, disasters and humanitarian crises where WHO plays an essential role in supporting countries to respond to and recover from emergencies with public health consequences.”

Crisis in Tigray, Ethiopia [Last apparent update: 5 Aug 2021]


Ebola outbreak outbreak, N’Zerekore, Guinea, 2021 [Last apparent update: 17 Aug 2021]
Coronavirus disease (COVID-19) pandemic  [See COVID above]


Ebola outbreak, Democratic Republic of the Congo, 2018  [Last apparent update: 24 July 2018]

Yemen crisis  [Last apparent update: 12 February 2021]

Syria crisis  [Last apparent update: 18 June 2021]

Somalia crisis  [Last apparent update: 24 March 2018]

Nigeria crisis  [Last apparent update: 9 May 2018]


Zika virus disease outbreak, 2015-2016  [Last apparent update: 24 Jan 2020]


Iraq crisis  [Last apparent update: 9 Jan 2008]

South Sudan crisis  [Last apparent update: 23 Sep 2020]

Avian influenza A (H7N9) virus outbreak
:: 13 September 2021  News release
Upcoming WHO Consultation on the Composition of Influenza Virus Vaccines for the Southern Hemisphere 2022

Middle East respiratory syndrome (MERS-CoV) outbreak  [Last apparent update: 8 July 2019]

Influenza A (H1N1) virus, 2009-2010 pandemic  [Last apparent update: 10 Aug 2010]

::::::

UN OCHA – Current Emergencies
Current Corporate Emergencies
Northern Ethiopia
Ethiopia - Tigray Region Humanitarian Update Situation Report, 2 Sep 2021

::::::
WHO & Regional Offices [to 04 Sep 2021]
https://www.who.int/

News
13 September 2021   News release
**Upcoming WHO Consultation on the Composition of Influenza Virus Vaccines for the Southern Hemisphere 2022**

3 September 2021   Departmental news
**Virtual cGMP Training Marathon for vaccine manufacturing**

3 September 2021   Departmental news
**WHO and UN partners’ compendium of 500 actions aims to reduce diseases from environmental factors and save lives**

2 September 2021   News release
**World failing to address dementia challenge**

1 September 2021   News release
**WHO, Germany open Hub for Pandemic and Epidemic Intelligence in Berlin**

1 September 2021   Departmental news
**What’s needed to improve safety and quality of abortion care?**

31 August 2021   News release
**WHO releases new compendium of innovative health technologies for COVID-19 and other priority diseases**

31 August 2021   Medical product alert
**Medical Product Alert N°5/2021: Falsified COVISHIELD vaccine (Update)**

30 August 2021   Departmental news
**Profile: Dr. Kwaku Poku Asante, Director at Kintampo Health Research Centre, Ghana Health Service**

Select Press Releases, Announcements

**WHO Regional Offices**

**WHO African Region**  AFRO

:: Afro-Move network helps track COVID-19 vaccine effectiveness   02 September 2021
As COVID-19 vaccines are rolled out in Africa, understanding the effectiveness of these vaccines in real world settings is crucial for countries to plan and refine their vaccination programmes and other public health measures.

:: Guinea’s swift action in detecting, curbing Marburg   02 September 2021
When a man in Temessadou M’Boket – a village in the densely forested southern Guinea region – died in early August 2021 after suffering fever, headache and haemorrhage, a medical team was quickly
dispatched, and within hours of his death, laboratory analysis revealed that he had been ill with Marburg.

**WHO Region of the Americas** PAHO

*No new digest content identified*

**WHO South-East Asia Region** SEARO

:: 3 September 2021  *News release* Health Ministers from WHO South-East Asia Region to discuss pandemic, rebuilding essential health services for UHC

**WHO European Region** EURO

:: WHO/Europe: stagnating COVID-19 vaccination uptake requires urgent action 30-08-2021
:: All schools in Europe and Central Asia should remain open and be made safer from COVID-19, say WHO and UNICEF 30-08-2021

**WHO Eastern Mediterranean Region** EMRO

:: Islamic Republic of Iran receives third delivery of COVID-19 vaccines through the COVAX Facility 2 September 2021
:: Germany donates 1.3 million face masks for COVID-19 response in Somalia 31 August 2021
:: Every sector in Syria has a role to play in addressing social determinants of health and influencing health outcomes 30 August 2021

**WHO Western Pacific Region**

*No new digest content identified*

::::::

**New WHO Publications** [Selected]

https://www.who.int/publications/i

3 September 2021
*Compendium of WHO and other UN guidance on health and environment*

1 September 2021
*Summary of Key Characteristics of WHO Prequalified Rotavirus Vaccines*

31 August 2021
*WHO compendium of innovative health technologies for low-resource settings 2021, COVID-19*

[See COVID above for detail]

*COVID-19 immunization in refugees and migrants: principles and key considerations: interim guidance,* ...

31 August 2021
[See Milestones above for detail]
CDC Announces More Than $300 Million in Funding to Support Community Health Workers
Friday, September 3, 2021

CDC launches COVID-19 resources for people with intellectual and developmental disabilities
Tuesday, August 31, 2021

CDC Statement Following ACIP Pfizer-BioNTech Vote
Monday, August 30, 2021
[See COVID-USA above for detail]

Coronavirus Disease 2019 (COVID-19)- CDC
Approximately 50 announcements/reports/data summaries.
9/3/21
EARLY RELEASE: Hospitalizations Associated with COVID-19 Among Children and Adolescents — COVID-NET, 14 States, March 1, 2020–August 14, 2021

::::

Africa CDC [to 04 Sep 2021]
http://www.africacdc.org/

Press Releases
African Vaccine Acquisition Trust delivers 12 000 doses of COVID-19 vaccine to the African Union

ADDIS ABABA, ETHIOPIA, 3 SEPTEMBER 2021 – The African Union (AU), through the Africa Centres for Disease Control and Prevention (Africa CDC), has worked with the African Vaccine Acquisition Trust (AVAT) to secure 12,000 doses of the Johnson and Johnson single-shot COVID-19 vaccine for the African Union Commission (AUC) staff, AU Embassies’ staff and their dependents. The vaccines were handed over to the African Union’s Medical Health Services Directorate (MHSD) today. They arrived on the 1st of September.

The vaccines, partly manufactured in South Africa, were imported with the support of the government of the Federal Democratic Republic of Ethiopia. Being able to offer vaccines to all AUC and AU Embassy staff and their dependents is also an important step in securing the AU’s business continuity...

Press Releases
France works with African partners to deliver 10 million vaccines to Africa
30 August 2021

::::
China CDC  http://www.chinacdc.cn/en/

National Health Commission of the People’s Republic of China [to 04 Sep 2021]  
http://en.nhc.gov.cn/  
News  
**Sept 4: Daily briefing on novel coronavirus cases in China**  
On Sept 3, 31 provincial-level regions and the Xinjiang Production and Construction Corps on the Chinese mainland reported 28 new cases of confirmed infections.

Research on link of COVID, cold chain urged  
Updated: 2021-09-01| CHINA DAILY

National Medical Products Administration – PRC [to 04 Sep 2021]  
News  
**Over 2.07b doses of COVID-19 vaccines administered in China**  
2021-09-03  
More than 2.07 billion doses of COVID-19 vaccines had been administered in China as of Wednesday, data from the National Health Commission showed on Sept 2.

CCDC Weekly - **Weekly Reports: Current Volume (3)**  
2021-09-03 / No. 36  
PDF of this issue  
:: Outbreak Reports: Five Independent Cases of Human Infection with Avian Influenza H5N6 — Sichuan Province, China, 2021  
:: Methods and Applications: The Establishment and Application of Mobile Electronic Surveillance System for Infectious Diseases with the Help of China — Sierra Leone, 2016-Present  
:: Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, June, 2021

Organization Announcements  
**Editor’s Note:**  
Careful readers will note that the number and range of organizations now monitored in our Announcements section below has grown as the impacts of the pandemic have spread across global economies, supply chains and programmatic activity of multilateral agencies and INGOs.

Paul G. Allen Frontiers Group [to 04 Sep 2021]  
News
No new digest content identified.

**BARDA – U.S. Department of HHS** [to 04 Sep 2021]  
[https://www.phe.gov/about/barda/Pages/default.aspx](https://www.phe.gov/about/barda/Pages/default.aspx)  
*News*  
No new digest content identified.

**BMGF - Gates Foundation** [to 04 Sep 2021]  
[https://www.gatesfoundation.org/ideas/media-center](https://www.gatesfoundation.org/ideas/media-center)  
*Press Releases and Statements*  
No new digest content identified.

**Bill & Melinda Gates Medical Research Institute** [to 04 Sep 2021]  
[https://www.gatesmri.org/](https://www.gatesmri.org/)  
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people  
No new digest content identified.

**CARB-X** [to 04 Sep 2021]  
[https://carb-x.org/](https://carb-x.org/)  
*News*  
No new digest content identified.

**Center for Vaccine Ethics and Policy – GE2P2 Global Foundation** [to 04 Sep 2021]  
[https://centerforvaccineethicsandpolicy.net/](https://centerforvaccineethicsandpolicy.net/)  
*News/Analysis/Statements*  
:: Past weekly editions and posting of all segments of *Vaccines and Global Health: The Week in Review* are available here.  

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 04 Sep 2021]  
[http://cepi.net/](http://cepi.net/)  
*Latest News*  
No new digest content identified.

**DARPA – Defense Advanced Research Projects Agency** [to 04 Sep 2021]  
*News*  
9/2/2021
DARPA Announces Researchers Selected to INCAS Program

Today, DARPA announced the researchers selected to its Influence Campaign Awareness and Sensemaking (INCAS) program. Research teams led by Smart Information Flow Technologies (SIFT), Protagonist Technology, University of Southern California Information Sciences Institute (ISI), University of Illinois Urbana-Champaign, and Uncharted Software will work to develop automated techniques and tools that aid U.S. analysts in the detection and sensemaking of geopolitical online influence campaigns. Additionally, teams led by Lockheed Martin Advanced Technology Laboratories and University of Maryland Applied Research Laboratory for Intelligence and Security (ARLIS) will support test, evaluation, and transition efforts of the resulting INCAS technologies.

Duke Global Health Innovation Center  [to 04 Sep 2021]
https://dukeghic.org/
   Our Blog
   No new digest content identified.

EDCTP  [to 04 Sep 2021]
http://www.edctp.org/
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
No new digest content identified.

Emory Vaccine Center  [to 04 Sep 2021]
http://www.vaccines.emory.edu/
   Vaccine Center News
   No new digest content identified.

European Vaccine Initiative  [to 04 Sep 2021]
http://www.euvaccine.eu/
   Latest News
   No new digest content identified.

Fondation Merieux  [to 04 Sep 2021]
http://www.fondation-merieux.org/
   News, Events
   Mérieux Foundation co-organized event
   World Rabies Day 2021: Celebrating action to maintain momentum
   September 6, 2021 - Virtual Event

Gavi  [to 04 Sep 2021]
https://www.gavi.org/
2 September 2021
Canada donates doses through COVAX – Nigeria, Kenya and Niger to receive first doses

30 August 2021
France donates 10 million doses to Africa through COVAX and AU

GHIT Fund  [to 04 Sep 2021]
https://www.ghitfund.org/newsroom/press
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that
No new digest content identified.

Global Fund  [to 04 Sep 2021]
News & Stories
New Global Fund Tools to Oversee Grant Investments
02 September 2021

Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]  [to 04 Sep 2021]
https://www.glopid-r.org/news/
No new digest content identified.

Hilleman Laboratories  [to 04 Sep 2021]
http://www.hillemanlabs.org/
Website reports “under maintenance” at inquiry

Human Vaccines Project  [to 04 Sep 2021]
http://www.humanvaccinesproject.org/
News
HVP COVID Report
Sep 02, 2021
Laurie Garrett: Is There a COVID-19 Endgame?
[Excerpt]
... Given all of this, what is the endgame for COVID-19?
That is the fundamental question. And it is the one I’ve been asking over and over. Instead of
endgame, what even is our strategy? We’re playing football without a coach and without anyone even
agreeing on which goal post we’re supposed to run to. We don’t have agreement on national
elimination as a strategy versus global eradication, which is the other extreme. We also have no clear
effort underway to genuinely ascertain zoonotic spread of this virus. With COVID, we know that the
ACE2 receptor in one form or another is in every single mammal. What this tells us is that eradication is
going to be incredibly difficult, probably impossible in terms of the firm meaning of the term. It is going
to be a permanent part of our environment now and it will be reentering the human species in spillover
events from animal populations for the rest of the 21st century.
We need to ask ourselves: what is a reasonable strategic goal? And then design everything accordingly. What we’re facing is a failure to have started with a strategic global plan to begin with. This is the same mess we’re in with climate change, and really all the great supra-national challenges of our time.

You don’t get to an endgame without a strategy. But asking about endgame matters because all military leaders will tell you that you don’t have a strategy until you have a strategic goal. If you don’t have a goal, then all you have is a list of tactics about which you will endlessly debate and that’s exactly where we are now. I don’t see how we easily get past this.

**IAVI** [to 04 Sep 2021]
https://www.iavi.org/newsroom
*Latest News*
September 1, 2021
**IAVI statement on results from Phase IIb Imbokodo HIV vaccine clinical trial**
*Janssen-sponsored trial in sub-Saharan Africa discontinued due to lack of efficacy.*

Pharmaceutical company Johnson & Johnson today announced the discontinuation of a Phase IIb HIV vaccine clinical trial known as *Imbokodo* (HVTN 705/HPX2008), sponsored by Janssen Vaccines & Prevention B.V., part of the Janssen Pharmaceutical Companies of Johnson & Johnson. Data showed the investigational HIV vaccine regimen did not prevent HIV infection in a population of young women in sub-Saharan Africa at high risk of acquiring HIV. Importantly, the investigational vaccine was found to be safe with no serious adverse events among trial participants.

“Though these results are disappointing, IAVI commends Janssen and the study investigators for their commitment to HIV vaccine science and to conducting the Imbokodo trial safely, ethically, and in global collaboration with public and private institutions as well as communities,” said Mark Feinberg, M.D., Ph.D., President and CEO of IAVI. “A safe, effective, broadly accessible HIV vaccine remains an urgent global health priority. Going forward, IAVI and our collaborators believe that the most promising new HIV vaccine approaches are those intended to induce broadly neutralizing antibodies.”...

**International Coalition of Medicines Regulatory Authorities [ICMRA]**
*Selected Statements, Press Releases, Research*
*No new digest content identified.*

**ICRC** [to 04 Sep 2021]
*Selected News Releases, Statements, Reports*
*No new digest content identified.*

**IFFIm**
http://www.iffim.org/
*Press Releases/Announcements*
*No new digest content identified.*
**IFRC** [to 04 Sep 2021]
Selected Press Releases, Announcements
No new digest content identified.

**Institut Pasteur** [to 04 Sep 2021]
Press Documents
No new digest content identified.

**IOM / International Organization for Migration** [to 04 Sep 2021]
News
No new digest content identified.

**ISC / International Science Council** [to 04 Sep 2021]
ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.
https://council.science/current/
News
No new digest content identified.

**IVAC** [to 04 Sep 2021]
https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html
Updates; Events
No new digest content identified.

**IVI** [to 04 Sep 2021]
http://www.ivi.int/
Selected IVI News, Announcements, Events
**IVI 20th International Vaccinology Course kicks off September 6, 2021: Registration open**

**Johns Hopkins Center for Health Security** [to 04 Sep 2021]
https://www.centerforhealthsecurity.org/news/center-news/
Center News
No new digest content identified.

**MSF/Médecins Sans Frontières** [to 04 Sep 2021]
http://www.msf.org/
Lifesaving TB medicines still out of reach for children in high-burden countries
Press Release 3 Sep 2021

Venezuela
Tracking mosquitoes to prevent malaria in Venezuela
Project Update 1 Sep 2021

Lebanon
Healthcare system in Lebanon disintegrates as political vacuum persists
Project Update 1 Sep 2021

Haiti
The long road to recovery for earthquake survivors in Haiti
Project Update 30 Aug 2021

National Academy of Medicine - USA [to 04 Sep 2021]
https://nam.edu/programs/
Selected News/Programs
No new digest content identified.

National Academy of Sciences - USA [to 04 Sep 2021]
News
No new digest content identified.

National Vaccine Program Office - U.S. HHS [to 04 Sep 2021]
https://www.hhs.gov/vaccines/about/index.html
Upcoming Meetings/Latest Updates
Upcoming Meetings
September 14-15, 2021 NVAC Meeting

NIH [to 04 Sep 2021]
News Releases
HIV Vaccine Candidate Does Not Sufficiently Protect Women Against HIV Infection
August 31, 2021 — No Safety Concerns Found in Imbokodo Sub-Saharan Africa Study.
An investigational HIV vaccine tested in the “Imbokodo” clinical trial conducted in sub-Saharan Africa posed no safety concerns but did not provide sufficient protection against HIV infection, according to a primary analysis of the study data. The Phase 2b proof-of-concept study, which began in November 2017, enrolled 2,637 women ages 18 to 35 years from five countries...
UNHCR Office of the United Nations High Commissioner for Refugees [to 04 Sep 2021]
Selected News Releases, Announcements

Unprecedented displacement in Central America and Mexico calls for urgent regional responsibility sharing
2 Sep 2021

SAN SALVADOR - Central America and Mexico are facing unprecedented pressure as the number of people seeking international protection rises at a time when access to asylum and territory is being limited through troubling border restrictions, said Gillian Triggs, UNHCR’s Assistant High Commissioner for Protection, on wrapping up a two-week mission to the region.

“In Mexico, Guatemala and El Salvador, I have seen the tremendous strain the region is under because of the increasing flows of refugees and migrants. Extraordinary efforts are being made by governments and civil society to address these challenges,” Triggs said.

In conversations with internally displaced people, asylum seekers and refugees, Triggs heard stories of sexual violence, death threats and extortion in communities controlled by criminal gangs that – often coupled with economic hardship and the effects of climate change – have forced nearly a million people from El Salvador, Guatemala, and Honduras to flee their homes....

‘After the airlift’. News Comment attributable to UN High Commissioner for Refugees Filippo Grandi

The evacuation from Kabul is coming to an end. A larger crisis is just beginning.
30 Aug 2021

The 1961 Statelessness Convention: 60 years of promoting and protecting the right to a nationality
30 Aug 2021
Press Releases, News Notes, Statements  [Selected]

Press release  09/02/2021
**Haiti earthquake: over half a million children at risk of waterborne diseases - UNICEF**

Press release  08/30/2021
**All schools in Europe & Central Asia should remain open and made safer from COVID-19, say WHO and UNICEF**

As millions of school children return to school across the European Region where the highly transmissible SARS-CoV-2 Delta variant is dominant, the WHO Regional Office for Europe and UNICEF ECARO call for schools to stay open.

**Unitaid  [to 04 Sep 2021]**
https://unitaid.org/

**Featured News**
No new digest content identified.

**Vaccine Equity Initiative  [to 04 Sep 2021]**
https://vaccineequitycooperative.org/news/

**News**
No new digest content identified.

**Vaccination Acceptance & Demand Initiative [Sabin]  [to 04 Sep 2021]**
https://www.vaccineacceptance.org/

**Announcements**
No new digest content identified.

**Vaccine Confidence Project  [to 04 Sep 2021]**
http://www.vaccineconfidence.org/

**News, Research and Reports**
INFODEMIC A Stanford Conference on Social Media and COVID Misinformation

Sep 4, 2021

Prof. Heidi Larson introduces Stanford University’s conference *Social Media and COVID Misinformation*. The conference engaged experts in the fields of biomedical ethics, public health, and cyber policy with representatives from social media companies, popular blog sites, and the public to examine the intersection of social media, ethics, and COVID misinformation.

Video: https://youtu.be/usrN7UXbPo

**Coronavirus global impact**

Launched April 2, 2020 and recurring every 3 days, Premise Data is utilizing its global network of Contributors to assess economic, social, and health sentiment surrounding the coronavirus (COVID-19).

**Vaccine Education Center – Children’s Hospital of Philadelphia  [to 04 Sep 2021]**
http://www.chop.edu/centers-programs/vaccine-education-center
Wellcome Trust [to 04 Sep 2021]
https://wellcome.ac.uk/news
News and reports
Opinion
Authors: Alison Doig, Modi Mwatsama
Countdown to COP26: four actions global leaders can take to tackle the climate crisis and improve health
1 September 2021

The Wistar Institute [to 04 Sep 2021]
Press Releases
The Wistar Institute Recruits Vaccine Researcher Amelia Escolano, Ph.D., and Immunologist Nan Zhang, Ph.D., as Assistant Professors
PHILADELPHIA — (Sept. 1, 2021) — The Wistar Institute, an international biomedical research leader in cancer, immunology and infectious diseases, welcomes Amelia Escolano, Ph.D., and Nan Zhang, Ph.D., as assistant professors.

Press Release
The Wistar Institute Appoints Italo Tempera, Ph.D., as Associate Director for Cancer Research Career Enhancement of Its Cancer Center
PHILADELPHIA — (Aug. 31, 2021) — The Wistar Institute announces the appointment of Italo Tempera, Ph.D., as Associate Director for Cancer Research Career Enhancement at the Institute’s Cancer Center. In this role, Tempera, who is also an associate professor in the Gene Expression & Regulation Program, will lead the educational mission of the Institute and its Cancer Center to train scientists and create workforce development programs in the life sciences.

WFPHA: World Federation of Public Health Associations [to 04 Sep 2021]
https://www.wfpha.org/
Latest News
No new digest content identified.

World Bank [to 04 Sep 2021]
Selected News, Announcements
No new digest content identified.

World Customs Organization – WCO [to 04 Sep 2021]
http://www.wcoomd.org/
Latest News – Selected Items
2nd edition of the Secretariat Note on the role of Customs in facilitating and securing the cross-border movement of situationally critical medicines and vaccines
May 2021
The objective of this document is to provide guidance with regard to the implementation by Members of the twelve measures outlined in the WCO Resolution on the Role of Customs in facilitating the cross-border movement of situationally critical medicines and vaccines, as well as provide information on WCO instruments and tools that can support the implementation of the Resolution, and on Members’ good practices.

Joint Indicative List of Critical COVID-19 Vaccine Inputs
7 Jul 2021
The joint indicative list seeks to compile information on the critical inputs for the manufacturing, distributing and administering of COVID-19 vaccines that has been produced by several organizations. It was first compiled by the WTO Secretariat as a working document to facilitate discussions at the WTO COVID-19 Vaccine Supply Chain and Regulatory Transparency Symposium that took place on 29 June 2021. The list is purely indicative and subject to further clarification, modification, and improvement based on inputs by pharma and customs experts. It is based on the HS 2017 version and is without prejudice to the actual tariff classification assigned by WTO Members’ customs administrations at the time of importation. The list has no legal status and is without prejudice to the rights and obligations of WTO Members.

World Organisation for Animal Health (OIE) [to 04 Sep 2021]
Press Releases, Statements
No new digest content identified.

WTO - World Trade Organisation [to 04 Sep 2021]
http://www.wto.org/english/news_e/news_e.htm
WTO News and Events
How can cooperation on trade contribute to the United Nations Environment Assembly (UNEA) process on plastic pollution?
2 September 2021
Event organized by UNCTAD, UNEP, the Forum on Trade, Environment and the SDGs, and the Government of Ecuador
Remarks by DDG Paugam
News item

::::::

ARM [Alliance for Regenerative Medicine] [to 04 Sep 2021]
Press Releases - Alliance for Regenerative Medicine (alliancerm.org)
Selected Press Releases
No new digest content identified.

BIO [to 04 Sep 2021]
Press Releases, Letters, Testimony, Comments [Selected]
No new digest content identified.

DCVMN – Developing Country Vaccine Manufacturers Network  [to 04 Sep 2021]
http://www.dcvmn.org/
News; Upcoming events
No new digest content identified.

ICBA – International Council of Biotechnology Associations  [to 04 Sep 2021]
https://internationalbiotech.org/news/
News
No new digest content identified.

IFPMA  [to 04 Sep 2021]
http://www.ifpma.org/resources/news-releases/
Selected Press Releases, Statements, Publications
No new digest content identified.

International Generic and Biosimilar Medicines Association [IGBA]
https://www.igbamedicines.org/
News
No new digest content identified.

International Alliance of Patients’ Organizations – IAPO  [to 04 Sep 2021]
https://www.iapo.org.uk/news/topic/6
Press and media [Selected]
No new digest content identified.

PhRMA  [to 04 Sep 2021]
http://www.phrma.org/
Latest News [Selected]
The impact of monoclonal antibodies and COVID-19 recovery
September 2, 2021
Monoclonal antibodies are a type of biologic medicine that play a central role in advancing our ability to treat a range of diseases.
Blog Post

* * * * *

Journal Watch
Vaccines and Global Health: The Week in Review continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: david.r.curry@centerforvaccineethicsandpolicy.org

AJOB Empirical Bioethics
Volume 12, 2020 Issue 3
https://www.tandfonline.com/toc/uabr21/current
[Reviewed earlier]

AMA Journal of Ethics
Volume 23, Number 9: E667-756 Sep 2021
https://journalofethics.ama-assn.org/issue/implantable-material-and-device-regulation

Implantable Material and Device Regulation
About 10% of Americans will have a device implanted into their bodies during their lifetimes. Fewer than 0.5% of these devices, however, are likely to have been tested in rigorous clinical trials generally regarded as standard by US regulators. Despite looser regulation of materials and devices than for pharmaceuticals, clinician-investigators and the Food and Drug Administration are obligated to balance patient-subjects’ safety with demand for patients’ timely access to technologies and interventions that might improve or extend their lives. This issue investigates that tension.

From the Editor
Sep 2021
How Differently Should the FDA Regulate Drugs and Devices?
Ariel Wampler, MD
This issue invites clinicians, researchers, device representatives, and patient-safety champions to consider how to exercise sufficient caution without stifling innovation.

AMA Code of Medical Ethics’ Opinions Related to Implantable Devices
Robert Dinallo
The AMA Code of Medical Ethics offers guidance for balancing need for safety with demand for innovation.

American Journal of Infection Control
September 2021 Volume 49Issue 9 p1093-1214
http://www.ajicjournal.org/current
Major Articles
Covid-19 vaccine acceptance, hesitancy, and refusal among Canadian healthcare workers: A multicenter survey
Stefania Dzieciolowska, Denis Hamel, Souleymane Gadio,...Leighanne Parkes, Ève Dubé, Yves Longtin
Published online: April 27, 2021 p1152-1157
American Journal of Preventive Medicine
September 2021  Volume 61Issue 3   p311-464
https://www.ajpmonline.org/current
Research Articles
Childhood Bacille Calmette-Guerin Vaccination and Its Association With Less Severe COVID-19 Pneumonia
Fan Chen, Guo X. Chen, Jing Zhou, Yun Xue, Mei X. Wu
Published online: April 12, 2021
e119-e126

American Journal of Public Health
July 2021  111(52)
http://ajph.aphapublications.org/toc/ajph/current
Supplement 2 2021
When Dying Really Counts
This new fully Open Access supplement issue looks at the urgent need to improve the quality of mortality data and routine surveillance in the context of COVID-19 and beyond. Consequences of inaccuracies in mortality data threaten the mission of public health, while challenges facing the professions of those who encounter and study death are facing unprecedented pressures

American Journal of Tropical Medicine and Hygiene
https://www.ajtmh.org/view/journals/tpmd/105/2/tpmd.105.issue-2.xml
[Reviewed earlier]

Annals of Internal Medicine
August 2021  Volume 174, Issue 8
http://annals.org/aim/issue
[Reviewed earlier]

Artificial Intelligence – An International Journal
Volume 298  September 2021
[New issue; No digest content identified]

BMC Cost Effectiveness and Resource Allocation
http://resource-allocation.biomedcentral.com/
(Accessed 04 Sep 2021)
[No new digest content identified]
BMJ Global Health
September 2021 - Volume 6 - 9
https://gh.bmj.com/content/6/9
Commentary
The economics of improving global infectious disease surveillance (2 September, 2021)
Linda de Vries, Marion Koopmans, Alec Morton, Pieter van Baal

Original research
Scared, powerless, insulted and embarrassed: hesitancy towards vaccines among caregivers in Cavite Province, the Philippines (2 September, 2021)
Jhoys Landicho-Guevarra, Mark Donald C Reñosa, Jonas Wachinger, Vivienne Endoma, Mila F Aligato, Thea Andrea Bravo, Jeniffer Landicho, Kate Bärnighausen, Shannon A McMahon

BMC Health Services Research
http://www.biomedcentral.com/bmchealthservres/content
(Accessed 04 Sep 2021)
[No new digest content identified]

BMC Infectious Diseases
http://www.biomedcentral.com/bmcinfectdis/content
(Accessed 04 Sep 2021)
Understanding the determinants of COVID-19 vaccination intention and willingness to pay: findings from a population-based survey in Bangladesh
Several coronavirus disease (COVID-19) vaccines have already been authorized and distributed in different countries all over the world, including Bangladesh. Understanding public acceptance of such a novel vac...
Authors: Rajon Banik, Md. Saiful Islam, Mamun Ur Rashid Pranta, Quazi Maksudur Rahman, Mahmudur Rahman, Shahina Pardhan, Robin Driscoll, Sahadat Hossain and Md. Tajuddin Sikder
Citation: BMC Infectious Diseases 2021 21:892
Content type: Research
Published on: 31 August 2021

BMC Medical Ethics
http://www.biomedcentral.com/bmcmedethics/content
(Accessed 04 Sep 2021)
[No new digest content identified]

BMC Medicine
http://www.biomedcentral.com/bmcmed/content
(Accessed 04 Sep 2021)
[No new digest content identified]
In the current COVID-19 pandemic, the world has reached an important milestone where vaccinations are discovered and are proven to be effective against SARS-COV-2 infections. Though vaccines against COVID-19 a...

Authors: Faheem Ahamed, Subhashini Ganesan, Anila James and Walid Abbas Zaher
Citation: BMC Public Health 2021 21:1602
Content type: Research
Published on: 30 August 2021
The genomic history of the Middle East
Mohamed A. Almarri, Marc Haber, Reem A. Lootah, Pille Hallast, Saeed Al Turki, Hilary C. Martin, Yali Xue, Chris Tyler-Smith

A high-coverage resource of physically phased genomes from eight Middle Eastern populations generated via linked-read sequencing provides insights into a genetically understudied region and enables more comprehensive study of population history and the detection of millions of variants common to the Middle East but outside short-read accessibility masks and not previously cataloged. It enhances our understanding of regional ancestry, the spread of languages, the effects of climate change on populations, and the evolutionary history of genetic variants.

Child Care, Health and Development
Volume 47, Issue 5 Pages: 575-731 September 2021
https://onlinelibrary.wiley.com/toc/13652214/current
[Reviewed earlier]

Clinical Pharmacology & Therapeutics
Volume 110, Issue 3 Pages: 519-825 September 2021
https://ascpt.onlinelibrary.wiley.com/toc/15326535/current

Pharmacogene Variation Consortium: A Global Resource and Repository for Pharmacogene Variation
Andrea Gaedigk, Scott T. Casey, Michelle Whirl-Carrillo, Neil A. Miller, Teri E. Klein
Pages: 542-545
First Published:06 June 2021

In this Perspective, we have briefly summarized the more recent origins and advances in the field of biologic pharmacogenetics under the academic discipline of vaccinomics. Although many advances have been made and are slowly being incorporated into how industry and biotechnology develops novel vaccine candidates, much more needs to be done. Interest in personalized applications of vaccines and drugs is evident; as one example, consider the tremendous rise in the demand for direct-to-consumer genetic testing. This interest will further accelerate as genetic-based testing becomes cheaper and offers more in-depth information. For example, our own work with the measles virus has uncovered SNPs in the CD46 and IFI44L genes that are associated with a substantial reduction in neutralizing antibody response to measles vaccine. Such findings allow the potential for reverse engineering a vaccine that can overcome such a barrier. Understanding why certain individuals are predisposed to specific AEs and which vaccines have a higher risk of eliciting those AEs will allow healthcare providers to match the right vaccine to the right recipient in order to minimize risks and maximize benefits...

Advancing Precision Medicine Through the New Pharmacogenomics Global Research Network
Kathleen M. Giacomini, Jason H. Karnes, Kristine R. Crews, Andrew A. Monte, William A. Murphy, Akinyemi Oni-Orisan, Laura B. Ramsey, Jun J. Yang, Michelle Whirl-Carrillo
Pages: 559-562
First Published:28 July 2021
Clinical Therapeutics
May 2021    Volume 43    Issue 5    p793-916
http://www.clinicaltherapeutics.com/current

Reviews

Advanced Therapies and Regulatory Framework in Different Areas of the Globe: Past, Present, and Future
Cleila Pimenta, Vitória Bettiol, Thuany Alencar-Silva,...Robert Pogue, Juliana Lott Carvalho, Maria Sueli Soares Felipe
Published online: April 21, 2021    e103-e138

Abstract
Purpose
The field of human medicine is in a constant state of evolution, developing and incorporating technological advances from diverse scientific fields. In recent years, cellular and gene therapies have come of age, challenging regulatory agencies to define the path for commercial registration. Approval necessarily demands robust evidence for safety and efficacy, but these exigencies must not be such that they render unviable the development and testing of the therapeutic agent. Furthermore, reimbursement strategies are required to guarantee commercial viability of these products, to avoid the risk that they will be removed from the market or become unavailable to most patients through lack of financial resources. To address such challenges, several countries have created strategies to manage advanced therapy products.

Methods
Based on official documents published by regulatory agencies worldwide, this review summarizes the current scenario in the United States, Europe, Brazil, Japan, South Korea, and China in this regard, discussing the harmonized and dissonant aspects of the regulatory framework in different regions of the world and exploring perspectives for the future.

Findings
The technical aspects of advanced therapies are increasingly complex, bringing challenges for high mass commercialization and demanding specific regulation. The regulatory framework of the analyzed regions is mainly recent and discordant, but many harmonizing initiatives were observed.

Implications
The comparative analysis of regulatory frameworks in different parts of the world is informative, as scientists must be aware of the rationale of regulators to assertively develop new technology and products that will be commercialized. The comparative analysis also provides insight into the main dissonances that must be addressed, fostering the harmonization of local regulatory frameworks. Many unanswered questions still lie ahead for the field of advanced therapies, and empirical evidence will be the most effective way to separate hype from hope and to establish the most sustainable mechanisms to regulate and finance such products in each part of the world.

Clinical Trials
Volume 18 Issue 4, August 2021
https://journals.sagepub.com/toc/ctja/18/4
[Reviewed earlier]

Conflict and Health
Contemporary Clinical Trials
Volume 107  August 2021
Research article  Open access
**Immunogenicity and safety of a live attenuated varicella vaccine in children 1–12 years of age: A randomized, blinded, controlled, non-inferiority phase 3 clinical trial**
Feng Jiang, Ruizhi Zhang, Qinghu Guan, Qiuyue Mu, ... Shiguang Lei
Article 106489

The CRISPR Journal
Volume 4, Issue 4 / August 2021
https://www.liebertpub.com/toc/crispr/4/4
[Reviewed earlier]

Current Genetic Medicine Reports
Volume 9, issue 3, September 2021
[Reviewed earlier]

Current Opinion in Infectious Diseases
August 2021 - Volume 34 - Issue 4
https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx
[Reviewed earlier]

Current Protocols in Human Genetics
Volume 108, Issue 1  December 2020
https://currentprotocols.onlinelibrary.wiley.com/toc/19348258/current
[Reviewed earlier]

Developing World Bioethics
Volume 21, Issue 3  Pages: 97-148  September 2021
https://onlinelibrary.wiley.com/toc/14718847/current
EDITORIAL
Free Access
**Vaccine nationalism – at this point in the COVID-19 pandemic: Unjustifiable**
Udo Schuklenk
Pages: 99
First Published: 01 September 2021
ORIGINAL ARTICLES

Allegations of misuse of African DNA in the UK: Will data protection legislation in South Africa be sufficient to prevent a recurrence?
Keymanthri Moodley, Anita Kleinsmidt
Pages: 125-130
First Published: 07 August 2020

Development in Practice
Volume 31, Issue 5, 2021
http://www.tandfonline.com/toc/cdip20/current
[Reviewed earlier]

Disaster Medicine and Public Health Preparedness
Volume 15 - Issue 3 - June 2021
https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue
[Website not responding at inquiry]

Disasters
Volume 45, Issue 3 Pages: 499-737 July 2021
https://onlinelibrary.wiley.com/toc/14677717/current
[Reviewed earlier]

EMBO Reports
Volume 22 Issue 8 4 August 2021
https://www.embopress.org/toc/14693178/current
[Reviewed earlier]

Emerging Infectious Diseases
Volume 27, Number 7—July 2021
http://wwwnc.cdc.gov/eid/
[Reviewed earlier]

Epidemics
Volume 36 September 2021
https://www.sciencedirect.com/journal/epidemics/vol/36/suppl/C
Research article Open access
Modeling the population effects of escape mutations in SARS-CoV-2 to guide vaccination strategies
James S. Koopman, Carl P. Simon, Wayne M. Getz, Richard Salter
Article 100484
Ethics, Medicine and Public Health
September 2021
Editorial  No access
COVID-19: The urgent call for academic research in research ethics
C. Bommier, H.-C. Stœklé, C. Hervé
Article 100679
Section snippets
Rebuilding the scientific ecosystem
Care has a price, research has a price: this engages ethical tensions with the Hippocratic oath and the archetype of scientific knowledge as a not marketable universal good. On the basis of this observation, the states have agreed worldwide to evaluate their scientists on a quantitative model: number of articles published, number of citations. As funding goes to the researchers with the highest number of articles and citations, this has favored the publication of a large number of articles at The need to develop university research ethics to foster a climate of scientific integrity
The development of university research in medical ethics has, until now, permitted a thorough reflection on the medical relationship and clinical research in the light of the human sciences and through a multidisciplinary approach. It is time for this reflection to be extended to the field of research integrity: indeed, ethical reflection in research can no longer be satisfied with the opinion of committees, since institutional research misconduct reports are always suspect of impartiality [5].

Research article  Abstract only
USoM platform. Proposal for an international and transdisciplinary interactive tool for centralization and anthropological exchange around human remains
A. Augias, S. Ben Amor, P. Charlier, G. Guerard
Article 100677

Research article  Abstract only
Ethical issues in genetics and infectious diseases research: An interdisciplinary expert review
Alexis Walker, Vence L. Bonham, Angie Boyce, Ellen Wright Clayton, ... Jeffrey Kahn
Article 100684
Research in genetics and infectious diseases (ID) presents novel configurations of ethical, legal, and social issues (ELSIs) related to the intersection of genetics with public health regulations and the
control of transmissible diseases. Such research includes work both in pathogen genetics and on the ways that human genetics affect responses to ID. This paper identifies and systematizes the unique issues at this intersection, based on an interdisciplinary expert review.

The European Journal of Public Health
SUPPLEMENT - Volume 31, Issue Supplement_1, July 2021
https://academic.oup.com/eurpub/issue/31/Supplement_1
Supplement: E-Mental-Health: Exploring the Evidence Base and Stakeholders’ Perspectives on Internet-Based Interventions for the Prevention of Mental Health Conditions

Mental illness represents an enormous personal, social and societal burden for European citizens\(^1\) calling for the need to expand existing models of mental healthcare delivery. In Europe, the Internet is a key source of health information,\(^2\) and technology-enhanced (psychological) interventions such as Internet- and mobile-delivered applications (‘eHealth’\(^3\) and ‘m-Health’\(^4\)) have become increasingly popular and studied. There is already strong evidence of the efficacy of online interventions for the prevention and treatment of several psychological disorders\(^5,6\) and meta-analyses show effect sizes similar to face-to-face interventions.\(^7\)

Expert Review of Vaccines
Vol 20 (7) 2021
https://www.tandfonline.com/toc/ierv20/current
Article
Expert opinion on the way forward for improving maternal influenza vaccination in India
Chittaranjan N. Purandare, Scott Preiss, Shafi Kolhapure & Sripriya Sathyanarayanan
Pages: 773-778
Published online: 31 May 2021

Review
Strategies to increase uptake of maternal pertussis vaccination
Kavin M. Patel, Laia Vazquez Guillamet, Lauren Pischel, Mallory K. Ellingson, Azucena Bardají & Saad B. Omer
Pages: 779-796
Published online: 21 Jul 2021

Article
Surveying willingness toward SARS-CoV-2 vaccination of healthcare workers in Italy
Gabriella Di Giuseppe, Concetta P. Pelullo, Giorgia Della Polla, Maria V. Montemurro, Francesco Napolitano, Maria Pavia & Italo F. Angelillo
Pages: 881-889
Published online: 25 May 2021

Forum for Development Studies
Volume 48, 2021 - Issue 2
http://www.tandfonline.com/toc/sfds20/current
[Reviewed earlier]
Politics and pandemics

This Special Issue of Global Public Health on Politics & Pandemics brings together 26 articles and commentaries that address diverse aspects of the politics of COVID-19 and related issues. These papers are grouped together in six topical areas: theories and politics of global health, health systems and policies, country responses, social inequalities, social responses, and the politics of science and technology. The goal of the Special Issue is to give readers a sense of the range of topics that have been a focus for research in relation to the COVID-19 pandemic and to provide diverse examples of how research and analysis on the political dimensions of the pandemic can contribute to confronting the COVID-19 crisis.

[Reviewed earlier]
Health and Human Rights
Volume 22, Issue 1, June 2020
Special Section: Mental Health and Human Rights
[Reviewed earlier]

Health Economics, Policy and Law
Volume 16 - Issue 3 - July 2021
https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue
[Reviewed earlier]

Health Policy and Planning
Volume 36, Issue 7, August 2021
https://academic.oup.com/heapol/issue/36/7
[New issue; No digest content identified]

Health Research Policy and Systems
http://www.health-policy-systems.com/content
[Accessed 04 Sep 2021]
[Reviewed earlier]

Human Gene Therapy
Volume 32, Issue 15-16 / August 2021
https://www.liebertpub.com/toc/hum/32/15-16
[Reviewed earlier]

Humanitarian Exchange Magazine
Number 79, May 2021
Localisation and local humanitarian action
by HPN October 2020
The theme of this edition of Humanitarian Exchange is localisation+ and local humanitarian action. Five years ago this week, donors, United Nations (UN) agencies, non-governmental organisations (NGOs), the International Committee of the Red Cross (ICRC) and International Federation of Red Cross and Red Crescent Societies (IFRC) committed within the Grand Bargain to increase multi-year investments in the institutional capacities of local and national responders, and to provide at least 25% of humanitarian funding to them as directly as possible. Since then, there is increasing consensus at policy and normative level, underscored by the Covid-19 pandemic, that local leadership should be supported. Localisation has gone from a fringe conversation among policy-makers and aid agencies in
2016 to a formal priority under the Grand Bargain. Wider global movements on anti-racism and
decolonisation have also brought new momentum to critical reflections on where power, knowledge
and capacity reside in the humanitarian system. Yet progress has been slow and major gaps remain
between the rhetoric around humanitarian partnerships, funding and coordination and practices on the
ground.

**Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)
Volume 17, Issue 5, 2021
https://www.tandfonline.com/toc/khvi20/current
[Reviewed earlier]

**Infectious Agents and Cancer**
http://www.infectagentscancer.com/content
[Accessed 04 Sep 2021]
*Knowledge and acceptance of HPV vaccination and its associated factors among parents of
daughters in Addis Ababa, Ethiopia: a community-based cross-sectional study*
Authors: Nebiyu Dereje, Abiga Ashenafi, Anteneh Abera, Efrata Melaku, Kaleb Yirgashewa, Meron
Yitna, Sarona Shewaye, Tsedenia Fasil and Yadel Yoseph
Content type: Research Article
3 September 2021

**Infectious Diseases of Poverty**
http://www.idpjournal.com/content
[Accessed 04 Sep 2021]
[No new digest content identified]

**International Health**
Volume 13, Issue 5, September 2021
https://academic.oup.com/inthealth/issue/13/5
**REVIEW ARTICLES**
*Institutional and behaviour-change interventions to support COVID-19 public health
measures: a review by the Lancet Commission Task Force on public health measures to
suppress the pandemic*
Jong-Koo Lee, Chris Bullen, Yanis Ben Amor, Simon R Bush, Francesca Colombo ...
International Health, Volume 13, Issue 5, September 2021, Pages 399–409,
https://doi.org/10.1093/inthealth/ihab022

**International Human Rights Law Review**
Volume 10 (2021): Issue 1 (Jun 2021)
https://brill.com/view/journals/hrlr/10/1/hrlr.10.issue-1.xml
[Reviewed earlier]
Programmatic evaluation of a school-based typhoid vaccination campaign: findings of qualitative research
Farhana Tabassum, Shanila Nooruddin, Atif Habib, Noshad Ali, Imtiaz Hussain, Alfred Pach, Zahid Memon, Sajid Soofi, Zulfiqar A. Bhutta
DOI: 10.18203/2394-6040.ijcmph20213526

Knowledge and perceptions towards candidate COVID-19 vaccines among practicing physicians of Tamil Nadu: a cross-sectional pilot study
K. R. S. Sivapriya, A. Keerthana, Balaji Arumugam, R. Nivetha
DOI: 10.18203/2394-6040.ijcmph20213548

International Journal of Human Rights in Healthcare
Volume 14 Issue 1 2021
https://www.emerald.com/insight/publication/issn/2056-4902/vol/14/iss/1
Table of Contents
[Reviewed earlier]

International Journal of Infectious Diseases
August 2021 Volume 109 p1-324
https://www.ijidonline.com/current
Coronavirus (COVID-19) Collection
COVID-19 Vaccine Acceptance among Health Care Workers in the Kingdom of Saudi Arabia
Jad A. Elharake, Bayan Galal, Saleh A. Alqahtani,...Kaveh Khoshnood, Saad B. Omer, Ziad A. Memish
Published online: July 06, 2021
p286-293

JAMA
August 24/31, 2021, Vol 326, No. 8, Pages 685-778
https://jamanetwork.com/journals/jama/currentissue
[Reviewed earlier]

JAMA Network
COVID-19 Update September 4, 2021
These articles on COVID-19 were published across the JAMA Network in the last week.
Centralized Reminder/Recall for Human Papillomavirus Vaccination: Findings From Two States—A Randomized Clinical Trial
Dennis Gurfinkel, Allison Kempe, Christina Albertin, ... Heather Roth, Shivani Arora, Peter Szilagyi
Published online: April 09, 2021
p579-587
The importance of techquity—defined as the strategic development and deployment of technology in health care and health to advance health equity—was even more apparent after the events of 2020. COVID-19 upended access to care and illuminated the impact of structural racism as a cause for a widening gap of access during the pandemic. Black Lives Matter became more than a trending hashtag on Twitter, or a movement resulting in peaceful protests and calls for policy reform: it put additional focus on the issue of race as a social and not a biological construct and called into question the rationale for common practices in health care that were triggered by race. A notable example was the emerging realization that kidney function assessment was tied to race and hardwired into many of our electronic health records. The real-world evidence around our lack of techquity was incontrovertible.

This Supplemental Issue of JHCPU provides articles that describe challenges to techquity, frameworks to improve the role of technology in care, and examples of how technology can transform health, public health, and health care...
Extended essays

**Justice in COVID-19 vaccine prioritisation: rethinking the approach** (9 June, 2021) Free Rosamond Rhodes

**Abstract**

Policies for the allocation of COVID-19 vaccine were implemented in early 2021 as soon as vaccine became available. Those responsible for the planning and execution of COVID-19 vaccination had to make choices about who received vaccination first while numerous authors offered their own recommendations. This paper provides an account of how such decisions should be made by focusing on the specifics of the situation at hand. In that light, I offer an argument for prioritising those who are likely vectors of the disease and a criticism of the victim-focused priority proposals put forward by the US Centers for Disease Control and Prevention, the National Academies of Sciences, Engineering, and Medicine, the UK National Health Service, and others. I also offer thoughts on how those authors may have gone astray.
Journal of Public Health Policy
Volume 42, issue 2, June 2021
[Reviewed earlier]

Journal of Refugee & Global Health
Volume 4, Issue 1 (2021)
https://ir.library.louisville.edu/rgh/
[Reviewed earlier]

Journal of the Royal Society – Interface
September 2021 Volume 18 Issue 182
https://royalsocietypublishing.org/toc/rsif/current
Research articles
Comparison between one and two dose SARS-CoV-2 vaccine prioritization for a fixed number of vaccine doses
Edward M. Hill and Matt J. Keeling
Published:01 September 2021Article ID:20210214
The swift development of SARS-CoV-2 vaccines has been met with worldwide commendation. However, in the context of an ongoing pandemic there is an interplay between infection and vaccination. While infection can grow exponentially, vaccination rates are ...

Journal of Travel Medicine
Volume 28, Issue 6, August 2021
https://academic.oup.com/jtm/issue
[New issue; No digest content identified]

Journal of Virology
Volume 95 Number 16 July 2021
http://jvi.asm.org/content/current
[Reviewed earlier]

The Lancet
Sep 04, 2021 Volume 398 Number 10303 p817-930, e12-e13
https://www.thelancet.com/journals/lancet/issue/current
Comment
Optimising SARS-CoV-2 vaccination schedules
Cristobal Belda-Iniesta
... In summary, the question to be answered is whether the data published by Liu and colleagues, in combination with those previously published by Borobia and colleagues, are enough evidence to
initiate the modification of vaccination schedules. Alternatively, large academic phase 3 clinical trials could explore the protection against severe disease, intensive care unit admission, and SARS-CoV-2 mortality using heterologous schedules, but the time and effort that this work would entail should be carefully balanced against the potential benefits.

Articles

Safety and immunogenicity of heterologous versus homologous prime-boost schedules with an adenoviral vectored and mRNA COVID-19 vaccine (Com-COV): a single-blind, randomised, non-inferiority trial
Xinxue Liu, et al. with the Com-COV Study Group

The Lancet Child & Adolescent Health
Aug 2021 Volume 5 Number 8 p531-604, e28-e31
https://www.thelancet.com/journals/lanchi/issue/current
[Reviewed earlier]

Lancet Digital Health
Aug 2021 Volume 3 Number 8e 462-e533
https://www.thelancet.com/journals/landig/issue/current
[Reviewed earlier]

Lancet Global Health
Aug 2021 Volume 9 Number 8 e1028-e1175
https://www.thelancet.com/journals/langlo/issue/current
[Reviewed earlier]

Lancet Infectious Diseases
Aug 2021 Volume 21 Number 8 p1051-1192, e208-e257
https://www.thelancet.com/journals/laninf/issue/current
[Reviewed earlier]

Lancet Public Health
Aug 2021 Volume 6 Number 8 e534-e619
https://www.thelancet.com/journals/lanpub/issue/current
[Reviewed earlier]

Lancet Respiratory Medicine
Aug 2021 Volume 9 Number 8 p803-936, e69-e87
https://www.thelancet.com/journals/lanres/issue/current
[Reviewed earlier]
Maternal and Child Health Journal
Volume 25, issue 8, August 2021
[Reviewed earlier]

Medical Decision Making (MDM)
Volume 41 Issue 6, August 2021
http://mdm.sagepub.com/content/current
[Reviewed earlier]

The Milbank Quarterly
A Multidisciplinary Journal of Population Health and Health Policy
Volume 99, Issue 2  Pages: 329-599  June 2021
https://onlinelibrary.wiley.com/toc/14680009/current
[Reviewed earlier]

Nature
Volume 597 Issue 7874, 2 September 2021
https://www.nature.com/nature/volumes/597/issues/7874
[New issue; No digest content identified]

Nature Biotechnology
Volume 39 Issue 8, August 2021
https://www.nature.com/nbt/volumes/39/issues/8
[Reviewed earlier]

Nature Communications
https://www.nature.com/subjects/health-sciences/ncomms
(Accessed 04 Sep 2021)
[No new digest content identified]

Nature Genetics
Volume 53 Issue 8, August 2021
https://www.nature.com/ng/volumes/53/issues/8
[New issue; No digest content identified]

Nature Human Behaviour
Volume 5 Issue 8, August 2021
https://www.nature.com/nathumbehav/volumes/5/issues/8
Article | 22 June 2021 | Open Access
**Despite vaccination, China needs non-pharmaceutical interventions to prevent widespread outbreaks of COVID-19 in 2021**

Using data-driven epidemiological modelling, Yu et al. estimate that, even with increasing vaccine availability, China will have to maintain stringent non-pharmaceutical interventions for at least a year to prevent new widespread outbreaks of COVID-19.

Juan Yang, Valentina Marziano, Hongjie Yu

**Nature Medicine**
Volume 27 Issue 8, August 2021
[Reviewed earlier]

https://www.nature.com/nm/volumes/27/issues/8

**Nature Reviews Genetics**
Volume 22 Issue 8, August 2021
[Reviewed earlier]

https://www.nature.com/nrg/volumes/22/issues/8

**Nature Reviews Immunology**
Volume 21 Issue 8, August 2021
[Reviewed earlier]

https://www.nature.com/nri/volumes/21/issues/8

**Nature Reviews Drug Discovery**
Volume 20 Issue 8, August 2021
[Reviewed earlier]

https://www.nature.com/nrd/volumes/20/issues/8

**New England Journal of Medicine**
September 2, 2021 Vol. 385 No. 10
Perspective

**Fundamentals of Public Health: Population Health and Human Rights**
J. Frenk and O. Gómez-Dantés

The way a society protects and promotes human rights shapes public policies, determines the distribution of resources and access to services, and ultimately affects population health. Scholarship and action on human rights have been foundational to the public health field.

**Original Articles**

**Effectiveness of an Inactivated SARS-CoV-2 Vaccine in Chile**
A. Jara and Others

Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently needed to support decision making. A countrywide mass vaccination campaign with the use of an inactivated severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2) vaccine (CoronaVac) was conducted in Chile starting on February 2, 2021

**Editorials**

**Effectiveness of an Inactivated SARS-CoV-2 Vaccine**
A. Wilder-Smith and K. Mulholland

**Articles**

**Maternal Vaccination and Infant Influenza and Pertussis**
Stacey L. Rowe, Karin Leder, Kirsten P. Perrett, Nicole Romero, Terry M. Nolan, Nicola Stephens, Benjamin C. Cowie, Allen C. Cheng
Pediatrics, Sep 2021, 148 (3) e2021051076

**PharmacoEconomics**
Volume 39, issue 8, August 2021
[Reviewed earlier]

**PLoS Biology**
https://journals.plos.org/plosbiology/
(Accessed 04 Sep 2021)
[No new digest content identified]

**PLoS Genetics**
https://journals.plos.org/plosgenetics/
(Accessed 04 Sep 2021)
[No new digest content identified]

**PLoS Medicine**
http://www.plosmedicine.org/
(Accessed 04 Sep 2021)
**Building global health research capacity to address research imperatives following the COVID-19 pandemic**
Peter H. Kilmarx, Roger I. Glass
Perspective | published 31 Aug 2021 PLOS Medicine
https://doi.org/10.1371/journal.pmed.1003753

**PLoS Neglected Tropical Diseases**
http://www.plosntds.org/
Health care workers intention to accept COVID-19 vaccine and associated factors in southwestern Ethiopia, 2021
Abiy Tadesse Angelo, Daniel Shiferaw Alemayehu, Aklilu Mamo Dachew
Research Article | published 03 Sep 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0257109

Effective vaccine allocation strategies, balancing economy with infection control against COVID-19 in Japan
Satoshi Sunohara, Toshiaki Asakura, Takashi Kimura, Shun Ozawa, Satoshi Oshima, Daigo Yamauchi, Akiko Tamakoshi
Research Article | published 02 Sep 2021 PLOS ONE
https://doi.org/10.1371/journal.pone.0257107

Prehospital & Disaster Medicine
Volume 36 - Issue 4 - August 2021
https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue
[Reviewed earlier]
Public Health
Volume 196  Pages A1-A2, e1-e4, 1-228 (July 2021)
[Reviewed earlier]

Public Health Ethics
Volume 14, Issue 1, April 2021
http://phe.oxfordjournals.org/content/current
[Reviewed earlier]

Public Health Reports
Volume 136 Issue 4, July/August 2021
https://journals.sagepub.com/toc/phrg/136/4
[Reviewed earlier]

Qualitative Health Research
Volume 31 Issue 8, July 2021
https://journals.sagepub.com/toc/qhra/current
[Reviewed earlier]

Research Ethics
Volume 17 Issue 3, July 2021
http://journals.sagepub.com/toc/reab/current
[Reviewed earlier]

Reproductive Health
http://www.reproductive-health-journal.com/content
[Accessed 04 Sep 2021]
[No new digest content identified]

Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)
https://www.paho.org/journal/en
Selected Articles
[No new digest content identified]

Risk Analysis
Volume 41, Issue 7  Pages: 1047-1253  July 2021
Special Issue: Interdisciplinary Theory, Methods, and Approaches for Hazards and Disaster Research
[Reviewed earlier]

Risk Management and Healthcare Policy
[Accessed 04 Sep 2021]
[No new digest content identified]

Science
Volume 373 | Issue 6559 | 3 Sep 2021
https://www.science.org/toc/science/current
https://royalsocietypublishing.org/toc/rspb/current
[New issue; No digest content identified]

Science Translational Medicine
Volume 13 | Issue 609 | 1 Sep 2021
https://www.science.org/toc/stm/current
Reports
Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection
Richard A. Urbanowicz et al.
05 Aug 2021
Open Access
Antibody responses to SARS-CoV-2 variants increase after two doses of BNT162b2 vaccine in both previously infected and naïve individuals.

Social Science & Medicine
Volume 284 | September 2021
[Reviewed earlier]

Systematic Reviews
https://systematicreviewsjournal.biomedcentral.com/articles
[Accessed 04 Sep 2021]
[No new digest content identified]

Theoretical Medicine and Bioethics
Volume 41, issue 5-6, December 2020
[Reviewed earlier]
Travel Medicine and Infectious Diseases
Volume 42  July–August 2021
[Reviewed earlier]

Tropical Medicine & International Health
Volume 26, Issue 8  Pages: i-iv, 839-1013  August 2021
https://onlinelibrary.wiley.com/toc/13653156/current
[Reviewed earlier]

Vaccine
Volume 39, Issue 34  Pages 4759-4920 (9 August 2021)
https://www.sciencedirect.com/journal/vaccine/vol/39/issue/34
Conference info  Abstract only
Implementation strategies for the first licensed dengue vaccine: A meeting report
Noah Fongwen, Isabelle Delrieu, Leong Hoe Ham, Duane J. Gubler, ... Annelies Wilder-Smith
Pages 4759-4765

Discussion  Full text access
Marketing the COVID-19 vaccine and the implications for public health
Emmanuel Mogaji
Pages 4766-4768

Discussion  Full text access
COVID-19 vaccine roll-out in middle-income countries: Lessons learned from the Jordan experience
Ala’a Al-Shaikh, Nazeema Muthu, Chinara Aidyralieva, Maria Cristina Profili, Saverio Bellizzi
Pages 4769-4771

Research article  Open access
Reasons why children miss vaccinations in Western Kenya; A step in a five-point plan to improve routine immunization
Mary Agócs, Amina Ismail, Kenneth Kamande, Collins Tabu, ... Karen Hennessey
Pages 4895-4902

Value in Health
September 2021  Volume 24  Issue 9  p1237-1390
https://www.valueinhealthjournal.com/current
[New issue; No digest content identified]
Selected Content

**Characteristics associated with COVID-19 vaccine uptake among adults in England (08 December to 17 May 2021)**
Elise Tessier, Yuma Rai, Eleanor Clarke, Anissa Lakhani, Camille Tsang, Ashley Makwana, Heather Heard, Tim Rickeard, Shreya Lakhani, Partho Roy, Michael Edelstein, Mary Ramsay, Jamie Lopez Bernal, Joanne White, Nick Andrews, Colin Campbell, Julia Stowe
medRxiv 2021.08.27.21262422; doi: https://doi.org/10.1101/2021.08.27.21262422

**The impact of mental health and substance use issues on COVID-19 vaccine readiness: a cross sectional community-based survey in Ontario, Canada**
Kamna Mehra, Roula Markoulakis, Sugy Kodeeswaran, Donald Redelmeier, Mark Sinyor, James Mackillop, Amy Cheung, Emily E Levitt, Tracey Addison, Anthony J Levitt
medRxiv 2021.08.30.21262844; doi: https://doi.org/10.1101/2021.08.30.21262844

**Projected resurgence of COVID-19 in the United States in July—December 2021 resulting from the increased transmissibility of the Delta variant and faltering vaccination**
medRxiv 2021.08.28.21262748; doi: https://doi.org/10.1101/2021.08.28.21262748

**Psychological antecedents towards COVID-19 vaccination using the Arabic 5C validated tool: An online study in 13 Arab countries**
medRxiv 2021.08.31.21262917; doi: https://doi.org/10.1101/2021.08.31.21262917

**BNT162b2 vaccine booster dose protection: A nationwide study from Israel**
Yinon M. Bar-On, Yair Goldberg, Micha Mandel, Omri Bodenheimer, Laurence Freedman, Nir Kalkstein, Barak Mizrahi, Sharon Alroy-Preis, Nachman Ash, Ron Milo, Amit Huppert
COVID-19 vaccine hesitancy among Algerian medical students: a cross-sectional study in five universities
Mohamed Amine Kerdoun, Abdellah Hamza Henni, Assia Yamoun, Amine Rahmani, Rym Messaouda Kerdoun, Nazia Elouar
medRxiv 2021.08.29.21261803; doi: https://doi.org/10.1101/2021.08.29.21261803

medRxiv 2021.08.27.21262356; doi: https://doi.org/10.1101/2021.08.27.21262356

* * * *

Think Tanks et al

Brookings  [to 04 Sep 2021]
http://www.brookings.edu/
Upcoming Event
Accelerating COVID-19 vaccinations in Africa
11:00 AM - 12:00 PM EDT  Sep 15

Center for Global Development  [to 04 Sep 2021]
http://www.cgdev.org/page/press-center
Accessed 04 Sep 2021
[No new digest content identified]

Chatham House  [to 04 Sep 2021]
https://www.chathamhouse.org/
Accessed 04 Sep 2021
[No new digest content identified]

CSIS
https://www.csis.org/
Accessed 04 Sep 2021
Podcast Episode
Larry Gostin – “Mandates May Be The Only Way Out of This”
September 2, 2021 | By J. Stephen Morrison, H. Andrew Schwartz

Kaiser Family Foundation
https://www.kff.org/search/?post_type=press-release
[No new digest content identified]

Urban Institute  [to 04 Sep 2021]
https://www.urban.org/publications
Publications
[No new digest content identified]

* * * * *
* * * * *

Vaccines and Global Health: The Week in Review is a service of the Center for Vaccine Ethics and Policy (CVEP)/GE2P2 Global, which is solely responsible for its content, and is an open access publication, subject to the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc/3.0/). Copyright is retained by CVEP.

CVEP is a program of the GE2P2 Global Foundation – whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, PATH, and industry resource members Janssen/J&J, Pfizer and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

* * * * *
* * * * *